Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2015 May 1;25(9):1990-4. doi: 10.1016/j.bmcl.2015.03.013. Epub 2015 Mar 14.

Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors.

Author information

1
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA, USA. Electronic address: Michael_Boyd@vrtx.com.
2
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA, USA.

Erratum in

  • Bioorg Med Chem Lett. 2016 Jan 1;26(1):240.

Abstract

VX-787 is a first in class, orally bioavailable compound that offers unparalleled potential for the treatment of pandemic and seasonal influenza. As a part of our routine SAR exploration, carboxylic acid isosteres of VX-787 were prepared and tested against influenza A. It was found that the negative charge is important for maintaining potency and selectivity relative to kinase targets. Neutral carboxylic acid replacements generally resulted in compounds that were significantly less potent and less selective relative to the charged species.

KEYWORDS:

Influenza; Isostere; VX-787

PMID:
25827523
DOI:
10.1016/j.bmcl.2015.03.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center